PharmaMar will host a conference call with investors after lurbinectedin results are presented at ASCO

Madrid, June 3rd, 2019.- PharmaMar (MSE:PHM) will hold a conference call with investors on June 4th at 07:00 CST (14:00 CET) to discuss the positive results of the Phase II trial with lurbinectedin for the treatment of relapsed small cell lung cancer, recently presented at ASCO (American Society of Clinical Oncology) by Dr. Luis Paz-Ares. This teleconference will be attended by Dr. Luis Paz-Ares, Head of the Oncology Department at the Hospital Universitario 12 de Octubre in Madrid and main author of the study.

The teleconference will take place on June 4th at 07:00 CST (14:00 CET). The numbers to connect to the teleconference are 877-407-3102 (from USA or Canada), 201-493-6790 (other countries) and 900 834 236 for Spain. Interested parties can also follow the conference call and see the accompanying slides live via the following link: https://78449.themediaframe.com/dataconf/productusers/phm/mediaframe/30603/indexl.html.

The recording of the teleconference can be accessed on PharmaMar's website by visiting the Events Calendar section of the Company's website www.pharmamar.com.

The results of this trial, in addition to being chosen for an oral presentation, have been chosen for the "Best of ASCO" meetings, where the highlights of the ASCO 2019 Annual Congress are selected.

Lurbinectedin has shown an Overall Response Rate (ORR) of 35.2% in the total population and 45% in patients with sensitive disease (CTFI≥90 days, i.e., those who have suffered a relapse of the disease in a period greater than or equal to 90 days) and 22.2% in patients with resistant disease (CTFI<90 days, i.e., those patients who have suffered a relapse of the disease in a period less than 90 days).

Additional Study Results

- The Disease Control Rate (DCR) was 68.6% in the overall population, 81.7% in sensitive patients and 51.1% in resistant patients.
- The median Duration of Response (DOR) was 5.3 months in the overall population, 6.2 months in sensitive patients and 4.7 months in resistant patients.
- The median Progression Free Survival (PFS) was 3.9 months in the overall population, 4.6 months in sensitive patients, and 2.6 months in resistant patients.
- The median Overall Survival (OS) was 9.3 months in the overall population, 11.9 months in sensitive patients, and 5.0 months in resistant patients.

In terms of product efficacy and safety, lurbinectedin has shown a favorable and manageable safety profile. The most common treatment-related adverse effects have been neutropenia, nausea or vomiting, and fatigue.

Grade 3-4 neutropenia occurred in 22.9% of cases, grade 3-4 febrile neutropenia in only 4.8%, grade 3-4 anemia in 6.7%, and grade 3-4 thrombocytopenia in 4.8%.

The single-agent lurbinectedin study is a single-arm, Phase II, multicenter trial, involving 105 patients recruited from 39 centers in nine countries in Western Europe along with the USA, studying the safety and efficacy of lurbinectedin in the second line treatment of small cell lung cancer.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical enterprise, Zelnova Zeltia. To learn more about PharmaMar, please visit us at www.pharmamar.com.

About lurbinectedin

Lurbinectedin (PM1183) is a synthetic compound currently under clinical investigation. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Digital Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000

Investor Relations:

Phone: +34 914444500

Or please visit our website at www.pharmamar.com